#RNAZ

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma TransCode Therapeutics (NASDAQ: RNAZ) reported preclinical data showing its lead candidate TTX-MC138 reaches orthotopic glioblastoma tumors after intravenous dosing and produces sustained target engagement against miR-10b.The study in murine models reported a 5-fold increase in apoptotic activity in tumors and a statistically significant survival benefit. IND‑enabling studies, PK/biodistribution, and toxicity work have been completed, and Phase 1 safety data exist in non-CNS patients; a Phase 2a trial is anticipated in H1 2026.

2 months ago

#RNAZ TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months in 44% of patients Safety and durability profile consistent with known mechanism of action Early signals support advancement to a Phase 2 a clinical trial with...

5 months ago

#RNAZ TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

10 months ago

News; ( NASDAQ: #RNAZ ) RNAZ announced stock split 1-28

0 0 0 0

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported TransCode Therapeutics (NASDAQ: RNAZ) has announced successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138. Key highlights include: - 15 patients treated across 4 dose levels (0.8 mg/kg to 4.8 mg/kg) - No significant safety or dose-limiting toxicities reported - 10 patients remain on study with stable disease - Two patients received 7 doses over ~7 months showing stable disease - PK/PD data shows predictable dose-response relationship - Evidence of miR-10b target engagement at 24 hours post-infusion in Cohorts 1 and 2 - Safety Review Committee approved expanded enrollment in Cohort 3 The positive results support advancement to the Phase 1b dose expansion portion of the trial.

10 months ago

#RNAZ TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares Major stock consolidation reduces 23.3M shares to 833K. See how this reverse split impacts your holdings and TransCode's Nasdaq listing status. Get details.

10 months ago

#RNAZ TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing TransCode's reverse split will convert 23.3M shares to 833.6K, aiming for Nasdaq minimum bid compliance. See how this impacts your holdings.

10 months ago

#RNAZ TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode's Cancer Drug Achieves Major Safety Milestone: 13 Patients Show No Toxicity in Latest Trial Data Latest Phase 1a data reveals promising safety profile in metastatic cancer treatment. Two patients maintain stable disease after 7 months. See complete trial results.

10 months ago

#RNAZ TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum Key reverse stock split vote delayed as only 12.73% of shares represented. Virtual meeting rescheduled for May 2. Learn how this impacts your investment.

10 months ago

#RNAZ TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 TransCode Therapeutics (NASDAQ: RNAZ) has announced significant progress in its Phase 1 clinical trial of TTX-MC138, their lead therapeutic candidate designed to inhibit microRNA-10b in metastatic cancer. The first patient in Cohort 4 has received initial dosing, with two additional patients scheduled for treatment.Key highlights include:Ten patients treated across four cohorts at escalating dose levelsNo significant safety or dose-limiting toxicities reportedSeven patients remain on study for continued treatmentCohort 4 dosing is approximately 50% higher than Cohort 3Ongoing data analysis from Cohorts 1-3 shows pharmacokinetic and pharmacodynamic profiles consistent with preclinical results and Phase 0 trialThe Safety Review Committee has approved additional patient enrollment in Cohort 3 to further establish the safety profile of TTX-MC138.

11 months ago

#RNAZ TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials Just announced: $10M offering fuels TransCode's TTX-MC138 clinical trials. Includes strategic warrant coverage at $0.86. See full financing terms and growth strategy.

11 months ago

#RNAZ TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode's Cancer Drug Shows Perfect Safety Record as Trial Expands to Higher Doses TransCode's TTX-MC138 cancer therapy achieves key milestone with zero safety issues across 3 cohorts. Strong 67% patient retention and green light for increased dosing signals promising progress.

1 year ago

#RNAZ TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Shareholders Green-Light Warrant Changes: What This Means for RNAZ's Financial Future Shareholders approved issuance of common stock upon warrant exercises, including pricing adjustments and a cashless exercise option for Series D Warrants.

1 year ago

#RNAZ TransCode Therapeutics, Inc. Announces Results of Special Meeting

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

Clinical Trial Milestone: TransCode's Cancer Drug Shows Zero Toxicity While Doubling Dose TransCode reports successful completion of Cohort 3 dosing for TTX-MC138, with no safety concerns across all patients and 66% target inhibition, marking significant progress in cancer treatment.

1 year ago

#RNAZ TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Feb 5th - #GERN #VBN #RNAZ #QNTM #FUBO #AG #LAES #RXRX #BB #WULF #BTE #BTG #CPIX #KTTA #IREN #SMR #QBTS #PTON #CDE #BBAI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Shareholder Participation Crisis: TransCode's Critical Warrant Vote Stalls at 30% TransCode's Special Meeting postponed as shareholder participation falls short at 29.94%. Key warrant exercise proposals await vote, with new deadline set for February 24.

1 year ago

#RNAZ TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

1 year ago

JUST IN: ( NASDAQ: #RNAZ ) Double Digit Stock Gainers with News: SLXN, SYTA, TRIB, and BACK

0 0 0 0

TransCode's TTX-MC138 Cancer Trial Advances: First Patient Dosed in Cohort 3 with Doubled Dose TransCode Therapeutics advances Phase 1 trial of TTX-MC138 with strong safety profile and 66% target inhibition. Third cohort begins with doubled dosage following positive data.

1 year ago

#RNAZ TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode's Cancer Drug TTX-MC138 Advances to Final Trial Phase with Promising Safety Data TransCode's metastatic cancer therapeutic TTX-MC138 shows strong safety profile and effectiveness in Phase 1 trial, advancing to final cohort with doubled dosage.

1 year ago

#RNAZ TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News TransCode Therapeutics implements major share consolidation to maintain Nasdaq listing, reducing 17.2M shares to 696K. Split effective Dec. 4, adjusting all equity instruments.

1 year ago

#RNAZ TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

#StockMarket #news #stocks

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

1 year ago

#RNAZ TransCode Therapeutics, Inc. Announces $8 Million Private Placement

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

1 year ago

#RNAZ TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

www.stocktitan.net/news/RNAZ/trans-code-the...

0 0 0 0

1 year ago

Just In: ( NASDAQ: #RNAZ ) TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

#StockMarket #News

1 0 0 0